Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
ADC Drug DS-8201 Shows Strong Efficacy in Patients with Low HER2 Breast ...
The Latest Research and Development into the Antibody–Drug Conjugate ...
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug ...
Figure 1 from Visualization of Intratumor Pharmacokinetics of [fam ...
Figure 1 from DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA ...
FDA批准首个乳腺癌HER2低表达的靶向药物Enhertu(DS-8201a、T-DXd、Fam-trastuzumab Deruxtecan ...
FDA授予Enhertu(DS8201、trastuzumab deruxtecan、T-DXd)治疗HER2低表达的乳腺癌突破性疗法指定 ...
Trastuzumab-deruxtecan (DS-8201a, T-DXd) | Antibody-Drug Conjugate ...
A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS ...
(PDF) Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2 ...
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I ...
Trastuzumab deruxtecan (DS-8201a), a HER2-Targeting Antibody–Drug ...
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2 ...
Trastuzumab deruxtecan (DS-8201a), a HER2-Targeting Antibody-Drug ...
Safety, pharmacokinetics, and antitumour activity of trastuzumab ...
Trastuzumab Deruxtecan | Drug Description » ADC Review
ADC药物：过去的十年|FDA_新浪新闻
Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab ...
Figure 3 from DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA ...
(PDF) 370TiPA phase Ib, multicenter, open-label study of the antibody ...
Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T ...
DS-8201a - 平头哥
[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is ...
Abstract P2-17-03: Preclinical study of trastuzumab deruxtecan (T-Dxd ...
Abstract OT1-07-04: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ...
Enhertu ® (fam-trastuzumab deruxtecan-nxki or DS-8201a) formula, ADC ...
(PDF) [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor ...
Trastuzumab deruxtecan (DS-8201a) for Breast Cancer Clinical Trial 2023 ...
FDA批准首个非小细胞肺癌HER2突变的靶向药物Enhertu(DS-8201a,T-DXd)上市,这些知识点你都知道吗_全球肿瘤医生网
DS-8201a | Semantic Scholar
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a ...
已上市ADC：专利布局全景分析|FDA_新浪财经_新浪网
NCT03329690 (Clinical Trial/ DS-8201a - trastuzumab deruxtecan) » ADC ...
List of ADCs Targeting HER
Fam-trastuzumab deruxtecan-nxki « New Drug Approvals
Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs ...
Table 1 from The Latest Research and Development into the Antibody-Drug ...
Enhertu(DS-8201a）临床数据 - 知乎
Clinical Trials for Metastatic HER2-positive Breast Cancer | PPTX
优赫得|Enhertu|德曲妥珠单抗|Trastuzumab Deruxtecan|DS-8201a——药研档案
SMT evaluation of trastuzumab-deruxtecan (DS-8201a). Left: Tumor volume ...
Abstract A145: DS-8201a, a novel HER2-targeting ADC with a novel DNA ...
新型靶向药物DS-8201a和T-DM1疗效喜人！肺癌患者福音！
首款！不限癌种，重磅ADC获FDA加速批准
A phase II, multicenter, open-label study of [fam-] trastuzumab ...
日本第一三共制药开发了一个奇特的her2-ADC，代号DS-8201，一个单抗上有四个连接位点，挂了8个导弹，效果很好，... - 雪球
(PDF) 563PUpdated results of phase I study of trastuzumab deruxtecan ...
DS‐8201a, a new HER2‐targeting antibody–drug conjugate incorporating a ...
Bystander killing effect of DS‐8201a, a novel anti‐human epidermal ...
(PDF) 194TiPPhase III study of [fam-] trastuzumab deruxtecan (DS-8201a ...
(PDF) Bystander killing effect of DS-8201a, a novel anti-HER2 antibody ...
Six different payload release mechanisms of anti-Her2 ADCs. (A) The ...
干货！“魔法子弹”--ADC药物的临床前药效评估
Combination effect of DS-8201a and anti-CTLA-4 antibody. Antitumor ...
Antitumor effect of DS-8201a in EMT6-hHER2 syngeneic mouse model. A ...
(PDF) 183TiPA phase II study of [fam-] trastuzumab deruxtecan (DS-8201a ...
(PDF) Heterogenous and Low Expression of HER2 in Breast Cancer Overcome ...
晚期胃癌新药DS-8201(DS8201、Trastuzumab Deruxtecan、T-DXd)、ZW25、AMG199未来可期_全球肿瘤医生网
DS-8201中国申报上市 2022年3月21日，第一三共HER2 ADC新药Trastuzumab Deruxtecan（DS-8201）的 ...
DS-8201a Sensitive Cell Line_药靶模型_南京科佰生物科技有限公司
[PDF] DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA ...
Trastuzumab-deruxtecan (DS-8201a, T-DXd) | 德喜曲妥珠单抗 | Antibody-Drug ...
Trastuzumab deruxtecan | 德曲妥珠单抗 | HER2治疗剂 | TargetMol
DS-8201a Resistant Cell Line_药靶模型_南京科佰生物科技有限公司
放射性核素标记技术在抗体偶联药物（ADC）药代动力学研究中的应用 - 药明康德DMPK
ENHERTU(DS-8201a)说明书 - 知乎
结合ADC药王DS-8201a的临床前研究，解读《抗体偶联药物非临床研究技术指导原则》医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
DS-8201_胃癌_抗癌药物_全球肿瘤医生网
重磅！HER2阳性胃癌新药DS-8201获CDE拟突破性疗法认定
30097-X.jpg)
30604-6/asset/fa133f3d-73da-45fe-8ea3-4842ec649559/main.assets/gr1_lrg.jpg)
30088-9/asset/332ae45c-2bf4-488f-9a7a-4e945e909ae9/main.assets/gr3_lrg.jpg)
%20for%20Breast%20Cancer.png?md=1)
